Abstract

Pyridoxine-dependent epilepsy (PDE) is due to biallelic variants in ALDH7A1 (PDE-ALDH7A1). ALDH7A1 encodes α-aminoadipic semialdehyde dehydrogenase in lysine catabolism. We investigated the gamma aminobutyric acid (GABA) metabolism and energy production pathways in human PDE-ALDH7A1 and its knock-out aldh7a1 zebrafish model. We measured GABA pathway, and tricarboxylic acid cycle metabolites and electron transport chain activities in patients with PDE-ALDH7A1 and in knock-out aldh7a1 zebrafish. We report results of three patients with PDE-ALDH7A1: low paired complex I+II and complex II+III and individual complex IV activities in muscle biopsy in patient 1 (likely more severe phenotype); significantly elevated CSF glutamate in the GABA pathway and elevated CSF citrate, succinate, isocitrate and α-ketoglutarate in the TCA cycle in patient 3 (likely more severe phenotype); and normal CSF GABA pathway and TCA cycle metabolites on long-term pyridoxine therapy in patient 2 (likely milder phenotype). All GABA pathway metabolites (γ-hydroxybutyrate, glutamine, glutamate, total GABA, succinic semialdehyde) and TCA cycle metabolites (citrate, malate, fumarate, isocitrate, lactate) were significantly low in the homozygous knock-out aldh7a1 zebrafish compared to the wildtype zebrafish. Homozygous knock-out aldh7a1 zebrafish had decreased electron transport chain enzyme activities compared to wildtype zebrafish. We report impaired electron transport chain function, accumulation of glutamate in the central nervous system and TCA cycle dysfunction in human PDE-ALDH7A1 and abnormal GABA pathway, TCA cycle and electron transport chain in knock-out aldh7a1 zebrafish. Central nervous system glutamate toxicity and impaired energy production may play important roles in the disease neuropathogenesis and severity in human PDE-ALDH7A1.

Highlights

  • Pyridoxine-dependent epilepsy (PDE) (OMIM#266100) is due to biallelic variants in ALDH7A1 (PDE-ALDH7A1) [1,2,3]. α-Aminoadipic semialdehyde (α-AASA) dehydrogenase (EC 1.2.1.31) in the lysine catabolic pathway is encoded by ALDH7A1 [NM_001201377.2; GI: 1676439670; NM_001202404.2 GI: 1677703364] and its deficiency causes accumulation of α-AASA, Δ1- piperideine-6-carboxylate (P6C), and pipecolic acid (PA)

  • We report results of three patients with PDE-ALDH7A1: low paired complex I+II and complex II+III and individual complex IV activities in muscle biopsy in patient 1; significantly elevated cerebrospinal fluid (CSF) glutamate in the gamma aminobutyric acid (GABA) pathway and elevated CSF citrate, succinate, isocitrate and α-ketoglutarate in the TCA cycle in patient 3; and normal CSF GABA pathway and TCA cycle metabolites on long-term pyridoxine therapy in patient 2

  • GABA pathway and TCA cycle metabolites were measured in the remaining stored CSF samples of two patients, which were collected during their clinical management

Read more

Summary

Introduction

Pyridoxine-dependent epilepsy (PDE) (OMIM#266100) is due to biallelic variants in ALDH7A1 (PDE-ALDH7A1) [1,2,3]. α-Aminoadipic semialdehyde (α-AASA) dehydrogenase (EC 1.2.1.31) in the lysine catabolic pathway is encoded by ALDH7A1 [NM_001201377.2 (variant 1); GI: 1676439670; NM_001202404.2 (variant 2) GI: 1677703364] and its deficiency causes accumulation of α-AASA, Δ1- piperideine-6-carboxylate (P6C), and pipecolic acid (PA). Pyridoxine-dependent epilepsy (PDE) (OMIM#266100) is due to biallelic variants in ALDH7A1 (PDE-ALDH7A1) [1,2,3]. Α-Aminoadipic semialdehyde (α-AASA) dehydrogenase (EC 1.2.1.31) in the lysine catabolic pathway is encoded by ALDH7A1 [NM_001201377.2 (variant 1); GI: 1676439670; NM_001202404.2 (variant 2) GI: 1677703364] and its deficiency causes accumulation of α-AASA, Δ1- piperideine-6-carboxylate (P6C), and pipecolic acid (PA). All patients with biallelic pathogenic or likely pathogenic variants have elevated α-AASA/P6C in body fluids. PA was elevated in most of the patients with biallelic pathogenic or likely pathogenic variants in ALDH7A1 [9]. Seizure freedom is reported in about 75% of patients on pyridoxine therapy [12]. Pyridoxine-dependent epilepsy (PDE) is due to biallelic variants in ALDH7A1 (PDEALDH7A1). We investigated the gamma aminobutyric acid (GABA) metabolism and energy production pathways in human PDE-ALDH7A1 and its knock-out aldh7a1 zebrafish model

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call